Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV golimumab in active rheumatoid arthritis despite methotrexate
2005-003232-21Phase 3Completed
- Sponsor
- Janssen Biotech
- Start
- Sep 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of golimumab in rheumatoid arthritis (RA) (3 arms), sponsored by Janssen Biotech. Primary endpoint: ACR50 response at Week 14. Started Sep 2006; status: completed.
02
Drugs
golimumab
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2005-003232-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-003232-21.